Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target

Current Medicinal Chemistry

Volumn 17, Issue 27, 2010, Pages 3099-3108

  Manina, G ^a,b   Pasca, M R ^a   Buroni, S ^a   de Rossi, E ^a   Riccardi, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b EPFL   (Switzerland)

Author keywords

Cell wall; Cellular target; Mycobacterium tuberculosis; New drugs; Rv3790 (DprE1)

Indexed keywords

ARABINOGALACTAN; ARABINOSE; BENZAMIDE DERIVATIVE; BENZOTHIAZINONE DERIVATIVE; DECAPRENYLPHOSPHORYL BETA RIBOSE 2' EPIMERASE; DINITROBENZAMIDE DERIVATIVE; EPIMERASE; MANNAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BIOSYNTHESIS; DRPE1 GENE; DRPE2 GENE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTITUBERCULAR AGENTS; CARBOHYDRATE SEQUENCE; DRUG DESIGN; HUMANS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; POLYSACCHARIDES, BACTERIAL; RACEMASES AND EPIMERASES; TUBERCULOSIS;

EID: 77955626451     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791959693     Document Type: Article

References (58)

1. Lönnroth, K.; Raviglione, M. Global epidemiology of tuberculosis: prospects for control. Semin. Respir. Crit. Care Med., 2008, 29, 481-491.
2. Maartens, G.; Wilkinson, R.J. Tuberculosis. Lancet, 2007, 370, 2030-2043.
3. Chan, E.D.; Iseman, M.D. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis., 2008, 21, 587-595.
4. LoBue, P. Extensively drug-resistant tuberculosis. Curr. Opin.Infect. Dis., 2009, 2, 167-173.
5. Zhang, Y.; Yew, W. W. Mechanisms of drug resistance in Myco-bacterium tuberculosis. Int. J. Tuberc. Lung Dis., 2009, 13, 1320-1330.
6. Dhar, N.; McKinney, J.D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. Opin. Microbiol., 2007, 10, 30-38.
7. Jain, A.; Mondal, R. Extensively drug-resistant tuberculosis: cur-rent challenges and threats. FEMS Immunol. Med. Microbiol., 2008, 53, 145-150.
8. Zignol, M.; Hosseini, M.S.; Wright, A.; Weezenbak, C.L.; Nunn, P.; Watt, C.J. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis., 2006, 194, 479-485.
9. Sacchettini, J.C.; Rubin, E.J.; Freundlich, J.S. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat. Rev. Microbiol., 2008, 6, 41-52.
10. Comas, I.; Gagneux, S. The past and future of tuberculosis research. PLoS Pathog., 2009, 5, e1000600.
11. Lenaerts, A.J.; Degroote, M.A.; Orme, I.M. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol., 2008, 16, 48-54.
12. Riccardi, G.; Pasca, M.R.; Buroni, S. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol., 2009, 4, 597-614.
13. Palomino, J.C.; Ramos, D.F.; da Silva, P.A. New anti-tuberculosis drugs: strategies, sources and new molecules. Curr. Med. Chem., 2009, 16, 1898-1904.
14. Blasi, P.; Schoubben, A.; Giovagnoli, S.; Rossi, C.; Ricci, M. Fighting tuberculosis: old drugs, new formulations. Expert Opin. Drug Deliv., 2009, 6, 977-993.
15. Selzer, P.M.; Brutsche, S.; Wiesner, P.; Schmid, P.; Müllner, H. Target-based drug discovery for the development of novel antiin-fectives. Int. J. Med. Microbiol., 2000, 290, 191-201.
16. Rosamond, J.; Allsop, A. Harnessing the power of the genome in the search for new antibiotics. Science, 2000, 287, 1973-1976.
17. Moir, D.T.; Shaw, K.J.; Hare, R.S.; Vovis, G.F. Genomics and antimicrobial drug discovery. Antimicrob. Agents Chemother., 1999, 43, 439-446.
18. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, III, C.E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; White-head, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
19. Sassetti, C.M.; Boyd, D.H.; Rubin, E.J. Genes required for myco-bacterial growth defined by high density mutagenesis. Mol. Micro-biol., 2003, 48, 77-84.
20. Sassetti, C.M.; Rubin, E.J. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 12989-12994.
21. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H.W.; Neefs, J.M.; Winkler, H.; Va n Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylqui-noline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
22. Lamichhane, G.; Tyagi, S.; Bissai, W.R. Designer arrays for defined mutant analysis to detect genes essential for survival of My-cobacterium tuberculosis in mouse lungs. Infect. Immun., 2005, 73, 2533-2540.
23. Wei, J.R.; Rubin, E.J. The many roads to essential genes. Tu b e r c u -losis (Edinb)., 2008, 88, S19-24.
24. Zhang, Y. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 529-564.
25. Wehenkel, A.; Bellinzoni, M.; Graña, M.; Duran, R.; Villarino, A.; Fernandez, P.; Andre-Leroux, G.; England, P.; Takiff, H.; Cerveñansky, C.; Cole, S.T.; Alzari, P.M. Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. Biochim. Biophys. Acta, 2008, 1784, 193-202.
26. Molle, V.; Kremer, L. Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way. Mol. Mi-crobiol., 2010, 75, 1064-1077.
27. Schreiber, M.; Res, I.; Matter, A. Protein kinases as antibacterial targets. Curr. Opin Cell Biol., 2009, 21, 325-330.
28. Rustad, T.R.; Sherrid, A.M.; Minch, K.J.; Sherman, D.R. Hypoxia: a window into Mycobacterium tuberculosis latency. Cell. Micro-biol., 2009, 11, 1151-1159.
29. McKinney, J.D.; Höner zu Bentrup, K.; Muñoz-Elías, E.J.; Miczak, A.; Chen, B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R. Jr.; Russell, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 2000, 406, 735-738.
30. Glickman, M.S.; Cox, J.S.; Jacobs, W.R. Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell, 2000, 5, 717-727.
31. Park, H.D.; Guinn, K.M.; Harrell, M.I.; Liao, R.; Voskuil, M.I.; Tompa, M.; Schoolnik, G.K; Sherman, D.R.; Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Myco-bacterium tuberculosis. Mol. Microbiol., 2003, 48, 833-843.
32. Lin, M.Y.; Ottenhoff, T.H. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocr. Metab. Immune Disord. Drug Targets, 2008, 8, 15-29.
33. Darwin, K.H.; Ehrt, S.; Gutierrez-Ramos, J.C.; Weich, N.; Nathan, C.F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science, 2003, 302, 1963-1966.
34. Lin, G.; Li, D.; de Carvalho, L.P.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J. D.; Li, H.; Nathan, C. Inhibitors selective for mycobacterial versus human pro-teasomes. Nature, 2009, 461, 621-626.
35. Baker, E.N. Structural genomics as an approach towards understanding the biology of tuberculosis. J. Struct. Funct. Genomics, 2007, 8, 57-65.
36. Ioerger, T.R.; Sacchettini, J.C. Structural genomics approach to drug discovery for Mycobacterium tuberculosis. Curr. Opin. Microbiol, 2009, 12, 318-325.
37. Vicente, M.; Hodgson, J.; Massidda, O.; Tonjum, T.; Henriques-Normark, B.; Ron, E.Z. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol. Rev., 2006, 30, 841-852.
38. Fischbach, M.A.; Walsh, C.T. Antibiotics for emerging pathogens. Science, 2009, 325, 1089-1093.
39. Zhang, Y.; Post-Martens, K.; Denkin, S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov. Today, 2006, 11, 21-27.
40. Ginsberg, A.M. Emerging drugs for active tuberculosis. Semin. Respir. Crit. Care Med., 2008, 29, 552-559.
41. Makarov, V.; Manina, G.; Mikusova, K.; Möllmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.; Pasca, M.R.; Buroni, S.; Lucarelli, A.P.; Milano, A.; De Rossi, E.; Belanova, M.; Bobovska, A.; Dianiskova, P.; Kordulakova, J.; Sala, C; Fullam, E.; Schneider, P.; McKinney, J.D.; Brodin, P.; Christophe, T; Waddell, S.; Butcher, P.; Albrethsen, J.; Rosenkrands, I.; Brosch, R.; Nandi, V.; Bharath, S.; Gaonkar, S.; Shandil, R.K.; Balasubramanian, V.; Bal-ganesh, T; Tyagi, S.; Grosset, J.; Riccardi, G.; Cole, S.T. Ben-zothiazinones kill Mycobacterium tuberculosis by blocking arabi-nan synthesis. Science, 2009, 324, 801-804.
42. Barry, C.E.; Crick, D.C.; McNeil, M.R. Targeting the formation of the cell wall core of Mycobacterium tuberculosis. Infect. Disord. Drug Targets, 2007, 7, 182-202.
43. Alderwick, L.J.; Birch, H.L.; Mishra, A.K.; Eggeling, L.; Besra, G.S. Structure, function and biosynthesis of the Mycobacterium tuberculosis cell wall: arabinogalactan and lipoarabinomannan assembly with a view to discovering new drug targets. Biochem. Soc. Trans., 2007, 35, 1325-1328.
44. Umesiri, F.E.; Sanki, A.K.; Boucau, J.; Ronning, D.R.; Sucheck, S.J. Recent advances toward the inhibition of mAG and LAM synthesis in Mycobacterium tuberculosis. Med. Res. Rev., 2010, 30, 290-326.
45. Kaur, D.; Guerin, M.E.; Skovierová, H.; Brennan, P. J.; Jackson, M. Chapter 2: Biogenesis of the cell wall and other glycoconju-gates of Mycobacterium tuberculosis. Adv. Appl. Microbiol, 2009, 69, 23-78.
46. Wolucka, B.A. Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J., 2008, 275, 2691-2711.
47. Meniche, X.; de Sousa-d'Auria, C; Van-der-Rest, B.; Bhamidi, S.; Huc, E.; Huang, H.; De Paepe, D.; Tropis, M.; McNeil, M.; Daffé, M.; Houssin, C. Partial redundancy in the synthesis of the D-arabinose incorporated in the cell wall arabinan of Corynebac-terineae. Microbiology, 2008, 154, 2315-2326.
48. Mikusova, K.; Huang, H.; Yagi, T; Holsters, M.; Vereecke, D.; D'Haeze, W.; Scherman, M.S.; Brennan, P.J.; McNeil, M.R.; Crick, D.C. Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J. Bacteriol., 2005, 187, 8020-8025.
49. Christophe, T; Jackson, M.; Jeon, H.K.; Fenistein, D.; Contreras-Dominguez, M.; Kim, J.; Genovesio, A.; Carralot, J.P.; Ewann, F.; Kim, E.H.; Lee, S.Y; Kang, S.; Seo, M.J.; Park, E.J.; Skovierová, H.; Pham, H.; Riccardi, G.; Nam, J.; Marsollier, L.; Kempf, M.; Joly-Guillou, M.L.; Oh, T; Shin, W.K.; No, Z.; Nehrbass, U.; Brosch, R.; Cole, S.; Brodin, P. High content screening identifies decaprenyl-phosphoribose 2'-epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog., 2009, 5, e1000645.
50. Haagsma, A.C.; Abdillahi-Ibrahim, R.; Wagner, M.J.; Krab, K.; Vergauwen, K.; Guillemont, J.; Andries, K.; Lill, H.; Koul, A.; Bald, D. Selectivity of TMC207 towards mycobacterial ATP syn-thase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother., 2009, 53, 1290-1292.
51. Williams, K.J.; Duncan, K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr. Mol. Med., 2007, 7, 297-307.
52. Böttger, E.C.; Springer, B. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur. J. Pediatr., 2008, 167, 141-148.
53. Aubry, A.; Veziris, N.; Cambau, E.; Truffot-Pernot, C.; Jarlier, V.; Fisher, L.M. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Che-mother., 2006, 50, 104-112.
54. Ginsburg, A.S.; Grosset, J.H.; Bishai, W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis., 2003, 3, 432-442.
55. Pasca, M.R.; Degiacomi, G.; de Jesus Lopes Ribeiro, A.L.; Zara, F.; De Mori, P.; Heym, B.; Mirrione, M.; Brerra, R.; Pagani, L.; Pucillo, L.; Troupioti, P.; Makarov, V.; Cole, S.T.; Riccardi, G. Clinical isolates of Mycobacterium tuberculosis in four european hospitals are uniformly susceptible to benzothiazinones. Antimi-crob. Agents Chemother., 2010, 54, 1616-1618.
56. Centrone, C.A.; Lowary, T.L. Sulfone and phosphinic acid analogs of decaprenolphosphoarabinose as potential anti-tuberculosis agents. Bioorg. Med. Chem., 2004, 12, 5495-5503.
57. Pathak, A.K.; Pathak, V.; Suling, W.J.; Riordan, J.R.; Gurcha, S.S.; Besra, G.S.; Reynolds, R.C. Synthesis of deoxygenated al-pha(1->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis. Bioorg. Med. Chem., 2009, 17, 872-881.
58. Ayers, B.; Long, H.; Sim, E.; Smellie, I.A.; Wilkinson, B.L.; Fairbanks, A.J. Stereoselective synthesis of beta-arabino glycosyl sul-fones as potential inhibitors of mycobacterial cell wall biosynthesis. Carbohydr. Res., 2009, 344, 739-746.